Home
About
About Us
Team
Contact
News
Science
Our Science
Clinical trials
Expanded access policy
Pipeline
Career
Work in highlightll pharma
Join Us
中文
中文
|
中文
Home
About
News
Science
About
About Us
Team
Contact
Hangzhou Highlightll News
We strive to discover breakthrough medicines which would have high impact on health care
The current position：
Home
/
News
/
Company news
Return
Highlightll Pharmaceutical TLL-018 Achieved Breakthrough Results in a Phase II Trial for Rheumatoid Arthritis
January 29,2023 From:
Highlightll Pharmaceutical
Prev
Selective JAK1/TYK2 Inhibition: A Novel Way to Overcome Tofacitinib Resistance in RA?
Next
Vial Announces Enrollment of First Patient in Phase II Clinical Trial TLL018- 205 for the Treatment of Plaque Psoriasis Sponsored by Highlightll Pharmaceutical
Return List
